Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Melanoma · Acral Melanoma · Temozolomide · Apatinib · Camrelizumab · Neoadjuvant · Pathological Response

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Jun Guo, Director) · guoj307@126.com · 13911233048

Study leads

Jun Guo
Principal Investigator
Peking University Cancer Hospital & Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Melanoma · Immune-related Adverse Event · Immune Checkpoint Inhibitor

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Shenzhen, China

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor · Melanoma · Head and Neck Cancer

Abroad (travel likely)RecruitingPHASE2

Duarte, United States · New Haven, United States

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Solid Tumor Cancer · Adult Refractory Cancer · Endometrial Carcinoma (EC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China · Beijing, China

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China